Mackenzie Financial Corp boosted its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 446.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,952 shares of the company's stock after purchasing an additional 106,153 shares during the quarter. Mackenzie Financial Corp owned about 0.09% of Xeris Biopharma worth $441,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in XERS. SG Americas Securities LLC grew its stake in Xeris Biopharma by 57.3% in the fourth quarter. SG Americas Securities LLC now owns 94,671 shares of the company's stock valued at $321,000 after acquiring an additional 34,469 shares during the period. Janney Montgomery Scott LLC grew its stake in Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock valued at $78,000 after acquiring an additional 5,500 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Xeris Biopharma by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company's stock valued at $107,000 after acquiring an additional 2,954 shares during the period. Legato Capital Management LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at about $482,000. Finally, Rhumbline Advisers grew its stake in Xeris Biopharma by 4.3% in the fourth quarter. Rhumbline Advisers now owns 180,964 shares of the company's stock valued at $613,000 after acquiring an additional 7,408 shares during the period. Institutional investors own 42.75% of the company's stock.
Xeris Biopharma Trading Up 2.7%
Shares of XERS stock traded up $0.12 on Friday, hitting $4.58. 1,820,428 shares of the stock were exchanged, compared to its average volume of 1,973,123. The firm has a market capitalization of $716.24 million, a P/E ratio of -10.18 and a beta of 0.71. The business has a 50-day moving average of $4.56 and a 200 day moving average of $4.07. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $6.07.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Oppenheimer boosted their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Craig Hallum boosted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. Leerink Partners boosted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.
Get Our Latest Report on XERS
Insider Buying and Selling
In related news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.47% of the stock is currently owned by corporate insiders.
Xeris Biopharma Profile
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
